Astellas Pharma Inc.
Notice Regarding Executive Personnel Changes
Astellas Pharma plans to decide on executive personnel changes at the Annual General Meeting of Shareholders scheduled for June 19, 2026. Kenji Yasukawa will be reappointed as Representative Chairman, and Naoki Okamura will be reappointed as Representative President and CEO.
Key Figures
- Candidate for Representative Chairman: Kenji Yasukawa (Reappointment)
- Candidate for Representative President and CEO: Naoki Okamura (Reappointment)
- Candidate for New Audit and Supervisory Committee Director: Shigeki Takahara
AI要約
Overview of Executive Personnel Changes
Astellas Pharma has preliminarily decided at the 21st Annual General Meeting of Shareholders and Board of Directors meeting scheduled for June 19, 2026, to reappoint Kenji Yasukawa as Representative Chairman, Naoki Okamura as Representative President and CEO, and Katsuyoshi Sugita as Representative Executive Vice President. Additionally, reappointments and new appointments of outside directors and audit and supervisory committee directors have been announced. The newly appointed audit and supervisory committee director, Shigeki Takahara, possesses extensive experience in accounting and finance.
Planned Resignees and Future Structure
Outside directors Takashi Tanaka, Eriko Sakurai, and Mika Nakayama are scheduled to resign. The Board composition after approval at the Annual General Meeting is also disclosed, aiming to ensure stability and continuity of the management structure. Executive personnel changes are important measures that contribute to strengthening corporate governance and promoting management strategies.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
